Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
| Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
| Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Descovy | Emtricitabine /tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Invokamet | Canagliflozin and metformin hydrochloride | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024